, phosphorus, and total protein were determined using nephelometry. 5 Insulin, IGF-1, and rhGH-1 were measured by ELISA. Estradiol and IGFBP-3 were measured by radioimmunoassay.
Cytokine assays
Th e Bio-Plex® Human Cytokine 17-Plex panel was used with the Bio-Plex Suspension Array System (Bio-Rad, Hercules, CA, USA) to simultaneously profi le expression of 17 infl ammatory mediators in serum samples. [6] [7] [8] Th e cytokines analyzed were IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma, monocyte chemoattractant protein-1 (MCP-1), macrophage infl ammatory protein-1-beta, and TNF. Th e assay was performed according to the manufacturer's instructions. In brief, serum samples were thawed, centrifuged at 4,500 rpm for 3 minutes at 4°C, and incubated for 30 minutes with microbeads labeled with antibodies against one of the aforementioned cytokines. Aft er washing, the beads were incubated with the detection antibody cocktail, with each bead being specific to a single cytokine. Aft er another wash step, the beads were incubated with streptavidin-phycoerythrin for 10 minutes and washed. Cytokine concentrations were determined using an array reader. For each cytokine, a standard curve was generated using recombinant proteins to estimate protein concentration in the unknown sample.
Analysis
We used t -tests to compare diff erences between the clinical characteristics of survivors and nonsurvivors; t -tests were performed using SAS, version 9.1.3 (SAS, Inc., Cary, NC, USA) and SPSS, Release 11.0.1 (SPSS, Inc., Chicago, IL, USA). Th e values of p were adjusted using the Benjamini and Hochberg's false discovery rate method. 9 Principal component analysis (PCA) was used to assess whether proteomic assays of cytokines or other clinical chemistries provided independent information. PCA is a dimension reduction technique applied to complex data. In this method, a large number of highly correlated, and possibly nonorthogonal, experimental variables are replaced with a smaller number of uncorrelated, orthogonal variables called principal components, which are linear combinations of the original experimental variables. Th e PCA method calculates a covariance matrix of the predictors and produces an orthogonal transformation of ranked, independent eigenvectors. The elements of the eigenvectors describe the contribution of each experimental variable to the principal components, each of which corresponds to the monotonically decreasing eigenvalues of the covariance matrix. In practice, the first principal component describes the linear combination of experimental variables that accounts for the greatest amount of variability across the experimental space, the second principal component accounts for the next greatest amount of variability, and so on for all the principal components. Typically, only the fi rst 2-5 principal components are actively investigated, as they usually account for most variability across the experimental space. Th is analysis was performed using SAS 9.2 procedure FACTOR and STATISTICA 8.
To test whether combining proteomics with clinical variables improves prediction of patient mortality, we used the generalized additive model (GAM). GAM uses a backfi tting algorithm within a Newton-Raphson technique. GAMs are data-driven modeling approaches used to identify nonlinear relationships between predictive features and clinical outcome when a large number of independent variables exists. 10, 11 We used SAS 9.2 PROC GAM and STATISTICA 8.0 to fi t the GAM fi ttings with binary logit link function, applying multiple types of smoothers with automatic selection of smoothing parameters.
Because the data contained mostly nonlinear relationships between variables, we used multivariate adaptive regression splines (MARS), which is a nonparametric method using piecewise linear spline functions (basis functions) as predictors.
12 Th e MARS model is constructed in two stages. In the fi rst stage, basis functions are added until a prespecifi ed number are included. In the second stage, basis functions are deleted starting with the basis function that contributes the least to the model until an optimum model is reached. By allowing the model to take on many forms as well as interactions, we can use MARS to track the very complex data structures that are oft en present in high-dimensional data. Crossvalidation techniques were used within MARS to avoid overfi tting the classifi cation model. Th e optimal model selected is the one with the lowest generalized cross-validation score. Finally, to cross-validate the results of the gold standard clinical predictor model (i.e., TBSA, presence of inhalation injury, and age), we used a maximum of nine basis functions, allowed up to two-way interactions, and used 10-fold cross-validation. For the combined clinical predictor and proteomics feature model, we allowed for up to 30 basis functions, permitted up to two-way interactions, and selected the optimal model by using 10-fold cross-validation (Salford Systems, Inc.).
Results

Patient characteristics
Of the 332 patients, 288 survived at 1 year aft er injury ( Table 1 ) . Survivors were younger (8 ± 5 years vs. 9 ± 6 years of age; p ≤ 0.05), less severely burned (59 ± 16% TBSA vs. 78 ± 14% TBSA, 47 ± 23% third degree vs. 70 ± 22% third degree; both p ≤ 0.05), and predominantly male (71% vs. 52%; p ≤ 0.05).
Serum analyte concentrations differ between survivors and nonsurvivors
Levels of six cytokines signifi cantly diff ered between the two outcomes. IL-4, IL-12p70, and IL-13 were higher in survivors than in nonsurvivors ( Table 2 ) . Th e reverse was true for IL-10, IL-5, and MCP-1. Both ALT and AST were higher in nonsurvivors, indicating that a component of liver injury adversely aff ects outcome. BUN and creatinine values were also higher in nonsurvivors, suggesting that these individuals have a slightly greater degree of intravascular fl uid depletion.
Proteomics measurements provide independent information on burn mortality PCA was conducted, with the first two principal components being used to plot the data ( Figure 1 ). The corresponding loading values of the experimental variables are shown in Table 3 . Principal component 1 accounted for 27% of the variability across the experimental space and had heavy loadings (i.e., eigenvector elements ≥0.5) on IL-2, IL-4, IL-6, IL-10, GM-CSF, IL-12, and G-CSF ( Table 3 ). Principal component 2 explained an additional 16% of the variability. Principal component 2 had heavy loadings on the percentage TBSA and percentage third-degree burn ( Table 3 ). These data suggest that cytokine measurements provide significant additional information over that obtained using only the gold standard clinical variables.
Proteomics feature analysis by data-driven estimations
To determine which modeling method provides the best performance on these data, we analyzed the linear and spline components of the proteomics measurements by GAM. Mg 2+ and AST have signifi cant spline components, indicating that they do not satisfy classical assumptions for the use of linear modeling ( Table 4 ) . Thus, modeling methods that assume global linear relationships, such as logistic regression, will not eff ectively capture information in the proteomics measurements. For this reason, we applied a nonparametric modeling approach, the MARS method.
MARS modeling of burns outcome
Two predictive models for burn mortality were evaluated using MARS: (1) the clinical gold standard, which includes values for age, percentage burn, and presence of inhalation injury and (2) a combination of proteomics measurements and the clinical gold standard. Th e best MARS results for the fi rst model, as selected by the model with the lowest generalized cross-validation score, produced an overall accuracy of 88% ( Table 5 ). Variable importance is a relative measurement of a variable's contribution to the overall model performance. Th e variable importance for the optimal model was percentage burn (100%), inhalation injury (71%), and age (46%). Th is result is consistent with earlier logistic regression models, which showed that percentage burn is a major predictor of nonsurvival. However, because nonsurvivors constituted only a small proportion Cytokines and clinical chemistries (expressed as mean ± S.D.) were measured in serum samples collected upon entry into the study. Only those that signifi cantly differed between groups are shown. Comparisons were performed on log2-transformed data using a two-tailed t-test, with adjustment for false discovery rate (FDR). a2Macro = ␣-2 macroglobulin; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; Hap = Haptoglobin; IL = interleukin; MCP-1 = monocyte chemoattractant protein-1; SERCRE = serum creatinine; totBIL = total bilirubin. of the data, this model was only 52% correct in its prediction of nonsurvivors ( Table 5 ) . Th e calculated sensitivity for this test was 92.8%, and the specifi city was 56.1%. Th e second MARS model, selected as that with the lowest generalized cross-validation score, was signifi cantly better than the fi rst, producing an overall accuracy of 95%. For the small nonsurvivor group, this MARS model with the combined features produced 81% accuracy, a substantial gain over the fi rst model ( Table 5 ) . Th e calculated sensitivity for this test was 97.2%, and the specifi city increased to 76.6%. Th e performance of the two MARS models was compared using the area under the receiver operating characteristic (ROC) curve. For each model, the sensitivity versus 1-specifi city was calculated and plotted. In ROC analysis, a diagonal line starting at zero indicates that the output is a random guess. On the other hand, an ideal classifi er with a high true positive rate and a low false positive rate will produce a positively oriented curve that bends strongly toward the upper left quadrant of the plot. 13 Th e area under the curve (AUC) is a scalar value between 0.5 and 1.0, and it is equivalent to the probability that two cases, one chosen at random from each group, are correctly ordered by the classifi er.
14 Th e ROC curve for the combined proteomics MARS model was signifi cantly shift ed up and to the left of the ROC curve produced by the clinical data-only MARS model ( Figure 2 ) . Th e AUC for the clinical data-only MARS model was 0.82, whereas that for the combined proteomics model was 0.95. Together, these data indicate that proteomics data signifi cantly enhance model performance over that yielded by clinical assessments alone.
Features predictive of burn mortality
Th e most informative features in the combined MARS model were identifi ed by ranking the variable importance on a percentile scale. Th e six most signifi cant features in the combined MARS model were percentage TBSA (100%), MCP-1 (59.55%), presence of inhalation injury (56.83%), albumin (54.03%), Mg 2+ (45.20%), and α2-macroglobulin (51.46%; Table 6 ). Discriminant analysis was also used to identify features that related highly to outcome. Th is analysis showed that percentage TBSA, presence of inhalation injury, α2-macroglobulin, and other variables were linearly related to outcome according to a chi-square test, whereas the cytokine levels were not ( Table 6 ) . Th e predictive features and their interactions that generated the MARS basis functions used in the combined proteomics model are shown in Table 7 .
Discussion
Multiple models have been created to better predict burn mortality. In the 1960s Professor Serge Baux devised the Baux score for predicting mortality postburn (Percent Mortality = Age + Percent body burned). Older patients tend to have poorer outcomes than younger patients with comparable injuries. Moreover, patients with larger burns tend to do worse than patients with smaller burns. Like age and burn size, inhalation injury is an independent risk factor for mortality. 15, 16 Our group showed that outcome can be predicted in only 51% of patients using age, burn size, and presence of inhalation injury. 17 Models incorporating variables such as resuscitation, packed-cell volume at admission, base defi cit, serum osmolarity, sepsis, inotropic support, platelet count, creatinine, and ventilator dependency with age, burn size, and inhalation injury make it possible to predict survival in massive pediatric burns (>80% TBSA) with a high degree of accuracy. In adults, the FLAMES score (Fatality by Longevity, APACHE II score, Measured Extent of burn, and Sex) can better predict mortality than Smith's score (Age, TBSA, and presence of inhalation injury) or the Age-Risk score (Age and TBSA) 18 by using age, APACHE II score, percentage partial thickness burn, percentage full thickness burn, and sex to determine hospital mortality risk. However this model is undermined by the absence of inhalation injury, which has been associated with an eightfold increase in mortality. 16 In recent years, attempts have been made to incorporate patient's coagulation and infl ammatory parameters into standard clinical indices to better predict mortality. 19 Because multiorgan failure is associated with a systemic infl ammatory reaction mediated by cytokines and acute phase proteins, we explored whether the relative abundance of these and other factors could be used to improve the accuracy of patient outcome prediction based on clinical correlates. We deliberately chose a clinically noisy dataset to identify factors indicative of survival that are applicable to either gender and are robust enough to overcome the variation inherent in a patient population covering a large age range, diff erences in postburn admission, and diff erences in burn size and severity. To achieve this, we did not match the two patient cohorts (survivor and nonsurvivor) by any variable (e.g., age, burn size, inhalation injury status). We only restricted the analyses to blood samples collected between the time of admission and of the fi rst operation (typically within the fi rst 24 hours of admission). Th e analytes selected for this study were measured using clinical laboratory tests that are typically performed as part of routine clinical care or in the case of the cytokines, analytes that can be easily measured using standard clinical laboratory equipment. All can be measured within 6 hours of serum isolation, allowing for rapid assessment of patient status.
Despite diff erences in the patient population (nonsurvivors were older, with a higher percentage of females, greater incidence of inhalation injury, and larger, more severe burns), we identifi ed a series of analytes that signifi cantly diff ered between survivors and nonsurvivors at admission. We then identified a set of analytes that improved prediction of patient outcome. AST, ALT, BUN, creatinine, IL-4, IL-12p70, IL-13, IL-10, IL-5, and MCP-1 signifi cantly diff ered between surviving and nonsurviving patients ( Table 2 ). Th ese diff erences refl ect severe immune dysfunction, hypovolemia, and renal and/or liver dysfunction that occur as patients become septic or develop multiorgan failure, outcomes that result in death. Th e diff erences in the analytes were found early during the acute period and before the onset of sepsis or multiorgan failure, so they may actually be predictive of these events. Further studies are needed to address this possibility. PCA is a linear transformation technique and an unsupervised clustering procedure. Th e total commonality of the principal components was only 47%, which explained only a small portion of total variation in PCA. Th e GAM and MARS techniques, however, are supervised transformation techniques that extend the nonlinear association between the predictor and response variables. Th e unexplained variability can be better estimated by the nonlinear portion using MARS modeling when the model performance is compared using ROC or the overall accuracy of the models. Heterogeneity can also be examined using a generalized additive linear mixed model to take into account the unexplained variability in the models. Th e nonlinear model fi t was better than the linear model without a smoothing function, according to the models' Akaiki Information Criterion.
Using MARS modeling with clinical variables as the sole independent variables, we found that the outcome prediction accuracy was 93.8% in surviving patients. However, prediction accuracy was only 52.3% for nonsurviving patients. Including serum analyte proteomics data in the MARS model markedly improved predictive capability, allowing for accurate classifi cation of 96% of survivors and 81% of nonsurvivors. Importantly, the area under the ROC curve also showed signifi cant improvement, increasing to 0.95. Th is indicates that the overall combined model performs much better than the clinical variables-only model ( Figure 2 ).
Although biological rationalization of the elements within a MARS model is diffi cult, inspection of the ranked variable importance provides useful information about the features that contribute most to the model. Not surprisingly, percentage TBSA emerged as the single most important predictor ( Table 6 ). Of the cytokines and liver proteins, MCP-1 and α2 macroglobulin contributed most significantly to model performance. Both proteins also significantly differed between survivors and nonsurvivors ( Table 2 ) .
In addition to having superior performance on nonparametric data, MARS is able to capture feature interactions. Inspection of the MARS basis functions showed that TBSA had a signifi cant interaction with the presence of inhalation injury, age, IL-4, and measures of liver function including α2 macroglobulin, albumin, AST, and ALT ( Table 7 ) . Th ese data suggest that, in the group having the greatest percentage TBSA, the concomitant increase in age, liver injury, or IL-4-mediated infl ammation produces a synergistic interaction that adversely aff ects outcome.
Th e goal of this study was to demonstrate that proteomics data could be used to improve upon the prediction model typically used to estimate whether a burn patient will survive. Th e fact that this new model was able to detect signifi cant diff erences between nonsurvivors and survivors in our unique patient population should stimulate further testing of these fi ndings. Independent validation of this model will be necessary before this biosignature is clinically implemented to predict patient outcome. As this study was performed in children, expanding the current fi ndings to include adult burn patients is warranted given that postburn mortality signifi cantly increases with age. 
